Menu Search

Company Announcements

Adocia SA

ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting

LYON, France--(BUSINESS WIRE)--Aug. 29, 2024-- Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced oral presentations at EASD 2024, unveiling the latest results obtained on AdoShell® Islets, an immunoprotective hydrogel containing islets of Langerhans for the treatment of diabetes by cell therapy, and on AdoGel® Sema, a technology enabling the sustained release of semaglutide.

The 60th annual congress of the EASD (European Association for the Study of Diabetes) will be held from September 9 to 13, in Madrid, Spain.

AdoShell® Islets

  • Title: ADO12, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use
  • Day and Time: Friday, September 13, 2024 - 11:00 -11:15 a.m.
  • Session: Protection in Islet Transplantation (OP-37; 219)
  • Room: Madrid Hall
  • Authors: Anne-Lise Gaffuri, Xavier Gaume, Romain Besnard, Julie Brun, Camille Gautier, Ouardane Jouannot, Nicolas Laurent, Rosy Eloy, Karim Bouzakri, François Pattou, Olivier Soula
  • Links: More details, including the abstract, are available on the EASD website.

About AdoShell® Islets:

AdoShell® Islets is a new immunoprotective hydrogel encapsulating islets of Langerhans. This permeable hydrogel allows the diffusion of insulin and glucose while preventing the invasion of antibodies and immune cells. This implantable device, which is fully retrievable by laparoscopy, has the potential to enable islet transplantation without the need for immunosuppression, offering an unprecedented solution for curing people with diabetes.

AdoShell® Islets have shown sustained survival and functionality of human islets in vitro for over 4 months. This long-term survival has been confirmed in vivo in immunodeficient mice, with a stable insulin or C-peptide secretion over 3 months, absence of fibrotic encapsulation and survival of functional islets.

Adocia is currently working with regulatory authorities to validate a first clinical trial, which could take place as early as 2025.

AdoGel® Sema

  • Title: Development of a once-a-month formulation of semaglutide from an innovative injectable and biodegradable hydrogel
  • Day and time: Tuesday, September 10, 2024 - 14:00 -14:15
  • Session: Hot of the press novel incretins (B. SO 062 - oral 746)
  • Room: station 11
  • Authors: Romain Besnard, Audrey Marechal, Claire Mégret, Sana Hakim, Jenny Erales, Ulysse Naessens, Maud Fumex, Martin Gaudier, Olivier Soula, You-Ping Chan, Emmanuel Dauty
  • Links: More details, including the abstract, are available on the EASD website.

About AdoGel®:

Designed to enable the long-acting delivery of peptides, AdoGel® is currently being studied for semaglutide (GLP‑1). The unique AdoGel® technology aims to offer monthly or even quarterly peptide injections, replacing the weekly injections currently on the market.

The results showed that a regular release of semaglutide over one month associated with limited early release is achievable. This could be a real benefit for treatment efficacy and safety as well as patient compliance by limiting the injection frequencies and reducing side effects

About EASD

EASD 2024 is the 60th annual congress of the European Association for the Study of Diabetes (EASD), a non-profit medical scientific association that supports and promotes the application of diabetes research. The association was founded in 1965 and is one of the world's largest networks of diabetologists.

The congress brings together key opinion leaders, corporate executives, scientists, physicians, researchers, caregivers and students interested in diabetes and related topics. The aim of the EASD Annual Congress is to encourage excellence in diabetes management through research and education.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™Paris (Euronext: ADOC; ISIN: FR0011184241).

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2024, available at www.adocia.com . Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.

Adocia

Olivier Soula
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com

Ulysse Communication

Adocia Press & Investor Relations
Bruno Arabian
Nicolas Entz
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26

Source: Adocia